Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients

Clinical Nephrology

Volumn 60, Issue 3, 2003, Pages 168-175

  Armada, E ^a   Perez C ^a   Otero, A ^a   Esteban, J ^a   Camba, M ^a   Gayoso, P ^a   Suarez D ^a  

^a Section of Nephrology   (Spain)

Author keywords

Atherosclerosis; Calcium levofolinate; Folic acid; Hemodialysis; Hyperhomocysteinemia

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; FOLIC ACID; FOLINATE CALCIUM; FOLINIC ACID; HOMOCYSTEINE; POLY(METHYL METHACRYLATE); PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; UREA;

ADULT; AGE; AGED; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; KINETICS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PREVALENCE; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0141681142     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp60168     Document Type: Article

References (32)

1. Armada E, Pérez C, Otero A, Gayoso P, Rodriguez M, Esteban J 2001 Efecto de la suplementación con ácido fólico sobre los niveles de homocisteína en pacientes en HD. Nefrología 21: 167-173
2. Arnadottir M, Berg AL, Hegbrant J, Hultberg B 1999 Influence of haemodialysis on plasma total homocysteine concentration. Nephrol Dial Transplant 14: 142-146
3. Arnadottir M, Gudnason V, Hultber B 2000 Treatment with different doses of folic acid in haemodialysis patients: effects on folate distribution and aminothiol concentrations. Nephrol Dial Transplant 15: 524-528
4. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W 1995 Hyperhomocysteinemia and the risk of vascular disease in hemodialysis patients. J Am Soc Nephrol 6: 121-125
5. Bayes B, Pastor MC, Bonal J, Junca J, Romero R 2001 Homocysteine and lipid peroxidation in hemodialysis: role of folinic acid and vitamin E. Nephrol Dial Transplant 16: 2172-2175
6. Blake P, Daugirdas J 1996 Quantification and prescpription general principles. In: Jacobs C, Kjellstrand CM, Koch KM, Winchester JF (eds) Replacement of Renal Function by Dialysis. Kluwer Academic Publishers, Dordrecht, pp 619-656
7. 12 in uraemic patients on maintenance haemodialysis. Am J Nephrol 21: 294-299
8. Christen WG, Ajani UA, Glynn RJ, Hennekens CH 2000 Blood levels of homocysteine and increased risks of cardiovascular disease. Arch Intern Med 160: 422-434
9. 12. J Am Soc Nephrol 12: abstract
10. Födinger M, Wagner OF, Hörl WH, Sunder-Plassmann G 2001 Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int 59 (Suppl 78): S238-242
11. Guttormsen AB, Ueland PM, Svarstad E, Refsum H 1997 Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 52: 495-502
12. Hauser AC, Hagen W, Rehak P, Buchmayer H, Fodinger M, Papagiannopoulos M, Bieglmayer C, Apsner R, Koller E, Ignatescu M, Horl WH, Sunder-Plassman GS 2001 Efficacy of folinic versus folic acid for the correction of hyperhomcysteinemia in hemodialysis patients. Am J Kidney Dis 37: 758-765
13. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH 1999 The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340: 1449-1454
14. Jennete JC, Goldman D 1975 Inhibition of the membrane transport of folates by anion retained in uremia. J Lab Clin Med 86: 834-843
15. Lee HA, Choi JS, Ha KS, Yang DH, Chang SK, Hong SY 1999 Influence of 5,10-methylenetetrahydrofolate reductase gene polymorphism on plasma homocysteine concentration in patients with end-stage renal disease. Am J Kidney Dis 34: 259-263
16. Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ 1998 Drug and environmental factors associated with adverse pregnancy outcomes. Part III: Folic acid: pharmacology, therapeutic recommendations and economics. Ann Pharmacother 32: 1087-1095
17. Livant EJ, Tamura T, Johnston KE, Vaughan WH, Bergamn SM, Forehand J, Walthaw J 1994 Plasma folate conjugase activities and folate concentrations in patients receiving hemodialysis. J Nutr Biochem 5: 504-508
18. Massy ZA 1999 Reversal of hyperhomocyst(e)inemia in chronic renal failure - is folic or folinic acid the answer? Nephrol Dial Transplant 14: 2810-2812
19. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW 1998 Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97: 138-141
20. Perna AF, Ingrosso D, De Santo NG, Galletti P, Brunone M, Zappia V 1997 Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 8: 1899-1905
21. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW 1996 Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94: 2743-2748
22. Schmitz JC, Stuart RK, Priest DG 1994 Disposition of folic acid and its metabolites: a comparison with leucovorin. Clin Pharmacol Ther 55: 501-508
23. Selhub J, Miller JW 1991 The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosyl-methionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 55: 131-138
24. 6 in hemodialyzed patients. Preliminary results after 5 months of follow-up. Minerva Urol Nefrol 53: 57-59
25. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullamann D, Tishler PV, Hennekens CH 1992 A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 268: 877-881
26. Suliman ME, Anderstam B, Lindholm B, Bergstrom J 1997 Total, free and protein-bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 12: 2332-2338
27. Suliman ME, Qureshs AR, Barany P, Stenvinkel P, Divino JC, Anderstam BJ, Heimburger O, Lindholm B, Bergstrom J 2000 Hyperhomocysteinemia, nutritional status and cardiovascular disease in hemodialysis patients. Kidney Int 57: 1727-1735
28. Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J, Enzerberger B, Janata O, Winkelmayer WC, Paul G, Auinger M, Barnas U, Hörl WH 2000 Effect of high-dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna Multicenter Study. J Am Soc Nephrol 11: 1106-1116
29. Touam M, Zingraff J, Jungers P, Chadefaux- Vekemans B, Drueke T, Massy ZA 1999 Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and piridoxine therapy. Kidney Int 56: 2292-2296
30. Van Guldener C, Kulik W, Berger R, Dijkstra AD, Jakobs C, Reinjgoud DJ, Donker JM, Stehouwer C, de Meer K 1999 Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 56: 1064-1071
31. Yango A, Shemin D, Hsu N, Jacques PF, Dworkin L, Selhub J, Bostom AG 2001 1-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients Kidney Int 59: 324-327
32. Zittoun J, Tonelli AP, Marquet J 1993 Pharmacokinetic comparison of leucovorin and levoleucovorin. Eur J Clin Pharmacol 44: 569-573